Navigation Links
Chimerix Announces Late-Breaker Presentation at 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Annual Meeting
Date:9/16/2011

irus (HSV), and JC virus (JCV), for which there are no FDA-approved treatments or where patients have failed available treatments. There is no evidence of otherwise unexplained nephrotoxicity or myelosuppression in these immunocompromised patients. These data support positive interim results seen in CMX001's ongoing Phase 2 placebo-controlled clinical trial evaluating the safety, tolerability and ability of CMX001 to prevent or control CMV infection in R+ hematopoietic cell transplant (HCT) recipients.  

About CMX001

CMX001 is an oral Lipid-Antiviral-Conjugate (LAC) that delivers high intracellular levels of the active antiviral agent cidofovir-diphosphate.  Its broad spectrum activity against double-stranded DNA (dsDNA) viruses without the myelotoxicity and nephrotoxicity of current agents has the potential to improve outcomes for immunosuppressed patients.  In development for the treatment or prevention of life-threatening dsDNA viral diseases, more than 600 patients have been dosed with CMX001 in placebo-controlled clinical trials and open-label treatment protocols.  More than 300 of these individuals have received CMX001 under Emergency Investigational New Drug Applications (EINDs) or as part of the CMX001-350 Open-Label Study to help treat life-threatening dsDNA viral diseases for which there were no other therapeutic options.  CMX001 is also being developed as a biodefense countermeasure in the event of a smallpox release.  The growing body of evidence of CMX001's antiviral activity against all five families of dsDNA viruses that cause disease in humans, including smallpox, has strengthened the compound's potential as a dual-use product prescribed as a traditional pharmaceutical and stockpiled as a biodefense countermeasure.  

Clinical studies of CMX001 include an ongoing Phase 2 study for the prevention cytomegalovirus (CMV) in adult hematopoietic cell transplant patients (CMX001-201); a Phase 2 s
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Chimerix Initiates a Multi-dose Clinical Trial of the Companys Lead Compound, CMX001, for the Treatment for Smallpox Infection
2. Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox
3. Chimerix to Present at Two Upcoming Investor Conferences
4. Chimerix CEO George Painter, Ph.D., to Speak on Improving Biodefense Product Discovery and Development Strategies at Institute of Medicine Workshop
5. Chimerix Initiates Phase 2 Study of CMX001 in Stem Cell Transplant Recipients Seropositive for Cytomegalovirus
6. Chimerix Appoints Thomas Pitler, Ph.D., Vice President, Business Development
7. Chimerix to Present at 9th Annual BIO Investor Forum
8. Chimerix Reaffirms Its Commitment to CMX001 as a Medical Countermeasure for Smallpox and Broad-Spectrum Antiviral Agent
9. Chimerix to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
10. Chimerixs Antiviral CMX157 Demonstrates Positive Phase 1 Clinical Results With Favorable Pharmacokinetics, Safety and Tolerability
11. Chimerix Commences CMX001 Open-Label Clinical Study for the Treatment of Patients With Life-Threatening or Serious dsDNA Viral Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Ohio , Jan. 15, 2014  A novel wearable injector ... easy and painless for patients to self-inject prescription drugs in ... disorders, including cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to grow to $220B by 2018, according to analysts.   Many ...
(Date:1/14/2014)... AUSTIN, Texas , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... report results for the fourth quarter of 2013 on Monday, ... scheduled for release after the close of trading. ... a conference call to discuss the operating highlights and financial ...
(Date:1/14/2014)... Calif. , Jan. 14, 2014 The Brandeis Medical Center, ... Angeles a premier and affordable laser tattoo removal experience ... Dr. Brandeis, focus is in providing high quality cosmetic services with ... patients. " Southern California has seen ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... 2011 Omeros Corporation (Nasdaq: OMER ) today ... Regents of the University of California to a new series ... advance in the control of surgical and traumatic bleeding. ... represents a potential life-saving treatment for patients. With the withdrawal ...
... 5, 2011 CutisPharma, Inc. announced the introduction ... Mary,s Mouthwash compounding kits. These products complete the ... line already includes FIRST® - Mouthwash BLM, and ... FIRST® - Duke,s Mouthwash are comparable to those ...
Cached Medicine Technology:Omeros Licenses Novel Antifibrinolytic Agents 2Omeros Licenses Novel Antifibrinolytic Agents 3Omeros Licenses Novel Antifibrinolytic Agents 4CutisPharma Launches New Prescription Mouthwash Kits Expanding Product Line 2
(Date:4/17/2014)... pain relief targets that could be used to ... King,s College London made the discovery when researching ... of the body. , Dr Marzia Malcangio said: ... pain generation and our findings could help chemotherapy ... One potential side effect of some chemotherapy drugs ...
(Date:4/17/2014)... Colo. (April 17, 2014) Two recent papers ... researcher and colleagues may help scientists develop treatments ... Yellow fever, Japanese encephalitis and other disease-causing flaviviruses. ... biochemistry and molecular genetics at the School of ... Howard Hughes Medical Institute, and colleagues recently published ...
(Date:4/17/2014)... MAYWOOD, Il. (April 17, 2014) Doctors who ... disease called lymphangioleiomyomatosis (LAM) can face an agonizing ... progression of the disease and help relieve shortness ... lung transplants, and sirolimus can cause potentially fatal ... said pulmonologist Dr. Daniel Dilling, medical director of ...
(Date:4/17/2014)... Boston University School of Medicine (BUSM) have discovered ... in an experimental model. The findings, reported in ... Abuse , may lead to more effective treatments ... one of the leading causes of illness and ... economic impact by limiting the productivity of workers ...
(Date:4/17/2014)... NEW YORK (17 April 2014) Population Council scientists and ... is safe, stable, and can prevent the transmission of ... and rectum in animals: HIV, herpes simplex virus 2 ... provides the first data that the gel is effective ... of efficacy in the vagina against all three viruses ...
Breaking Medicine News(10 mins):Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2
... Dr Mukesh Haikerwal, today congratulated the Government on a ... // with the AMA, and which delivers for patients. ... that the draconian conditions and red tape associated with ... ,'The Government has agreed that the expertise in prescribing ...
... especially the mentally-ill patients and their caregivers. The speech revived ... which would permit the use of obligatory powers to enable ... present ‘treatability test’. ,The infamous ‘Bournewood gap’ is ... of the new bill, which will seek to improve the ...
... banned the use of hookah, or hubble-bubble, in the Pakistani ... were spoiling the younger// generation. ,A way of ... South Asia and the Middle East, the hookah, known as ... and motels in Pakistan, The Daily Times said. ...
... more delays in getting the lab results! - Says ... from University of Georgia has developed a diagnostic test using ... influenza, HIV, RSV etc., in just 60 seconds or even ... technique – which is detailed in the November issue of ...
... that about one in 10 U.S. adults suffer chronic pain that ... Americans have increased to a record average of just short of ... from the Centers for Disease Control and Prevention. ,The ... 80 years and nearly 75 for males. The gap in life ...
... know that they shouldn't smoke or be around smokers ... at a young age. In addition, a new research ... could develop serious liver injuries due to the effects ... research performed at Washington University School of Medicine in ...
Cached Medicine News:Health News:Government Strikes Right Balance with PBS Reform 2Health News:Nanotechnology Used For Detecting Viruses 2Health News:Nanotechnology Used For Detecting Viruses 3Health News:Non-Steroidal Anti-Inflammatory Drugs Can Cause Liver Damages 2Health News:Non-Steroidal Anti-Inflammatory Drugs Can Cause Liver Damages 3
... PLUS pachometers are acknowledged to be the ... pachometers available. These benefits are due to ... and smallest tip footprint available coupled with ... for every displayed reading. Thus corneal thickness ...
... versatile and uncomplicated use of the Leica ... obtained make it the instrument of choice ... cryostat applications. The open top stainless steel ... accessible and offers ample space for convenient ...
... the new style of Bright cryostat. ... OTF/AS cryostat, the new OTF5000 incorporates ... ever-reliable and powerful 5040 microtome. A ... package deals makes the range of ...
... The Leica TP1020 product family are ... a perfect combination of approved technology with ... processing and maximum safety for tissues at ... engineering design based on proven precision mechanics ...
Medicine Products: